J&J, Sinovac shoots less effective against Omicron Covid


A laboratory test has shown that the Johnson & Johnson vaccine produced “virtually no” antibody protection, and the Sinovac vaccine (one of the most widely used in the world) does not provide enough antibodies to neutralize the variant. Other news of covid, including a higher risk of myocarditis after infection, is also being reported.

Bloomberg: J&J Shot loses antibody protection against Omicron in lab study

Johnson & Johnson’s vaccine produced virtually no antibody protection against the omicron coronavirus variant in a lab experiment, underscoring the new strain’s ability to bypass a mainstay of the body’s defenses. The vaccine appears to provide some defense against omicron, possibly via other means such as stimulating immune cells, according to Penny Moore, a South African virologist. The results are consistent with other studies that show partial loss of activity against Covid-19 for a number of vaccines, with J&J’s antibody protection appearing particularly low in the lab test. (Sguazzin, 12/14)

Bloomberg: Sinovac provides inadequate shield against Omicron, studies find

The vaccine made by Sinovac Biotech Ltd., one of the most widely used in the world, does not provide enough antibodies in two doses to neutralize the omicron variant and boosters will likely be needed to improve protection, early results of the drug showed. laboratory. While the first two published studies of the Chinese vaccine and omicron differed on the extent of the degradation of the vaccine’s immune response, they both indicated that standard two-dose therapy would not be sufficient, which raises uncertainty about a vaccine that millions of people rely on. in China and in developing countries to protect themselves from Covid-19. (Hong, 12/14)

In other news on vaccine deployment –

CIDRAP: COVID infection linked to much higher risk of myocarditis than vaccines

British researchers estimate that 2, 1 and 6 more cases of myocarditis occur per 1 million people during the week after a dose of AstraZeneca / Oxford, Pfizer / BioNTech and Moderna COVID-19 vaccines, respectively, while SARS positive – The CoV-2 test was linked to much higher odds of this and other serious heart problems. The data, published today in Nature Medicine, also shows 10 more cases of myocarditis per 1 million people within 28 days after a second dose of Moderna, compared to 40 within 28 days after a positive COVID-19 test. Increased cases of pericarditis and abnormal heart rhythms have also been seen in people diagnosed with COVID-19, but not in those given any type of COVID-19 vaccine. (12/14)

AP: Launch of a toll-free number for home vaccine requests

Delaware health officials are launching a toll-free number to help people confined to home request coronavirus vaccines at home. People who cannot make it to vaccination locations due to disability, age or serious illness can call the toll-free number to be assessed and schedule a vaccination, the Ministry of Health said on Tuesday. Health and Social Services. (12/14)

AP: Over 11 million COVID vaccine doses administered in WA in past year

Since the first shipment of COVID-19 vaccines arrived in Washington state a year ago, more than 11.3 million doses of the vaccine have been administered statewide, according to health officials of State. The Washington State Department of Health said on Tuesday that more than 5.4 million Washington residents had received at least one dose of the vaccine. As of Monday, 81.7% of the population aged 12 and over in Washington received at least one dose and 75.3% are fully vaccinated, according to the state’s COVID-19 Dashboard. (12/14)

Stat: Will we still need Covid-19 boosters? Experts have theories

With the world facing the latest in a seemingly endless stream of coronavirus variants – and with optimistic rhetoric from manufacturers about the need for even more vaccines – you wouldn’t be alone if you wondered: Covid boosters will be. still a must? in our future? The simple truth is that at this point there is no definitive answer to this question. (Branswell, 12/15 /)

This is part of the KHN Morning Briefing, a summary of coverage of health policies by major news organizations. Sign up for an email subscription.


Comments are closed.